Definitive Contract 75N93018C00036
Award Date 7/31/18
Potential Completion Date 7/31/20
Potential Value $631K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Missoula, MT 59802, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This is a $598,808 firm fixed price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Inimmune Corp. The contract is for research on adjuvant discovery for vaccines and for autoimmune and allergic diseases. Inimmune Corp is a biotechnology company with expertise in synthetic chemistry, drug formulation, and pharmaceutical manufacturing. They have received...
- This $1.8 million firm fixed price contract was awarded by the National Institutes of Health National Institute of Allergy and Infectious Diseases to Inimmune Corp. of Missoula, Montana. The contract is for Phase II of the Small Business Innovation Research program topic 091 to develop a new Toll-like receptor 4 agonist for the treatment of allergic rhinitis. The research and development effort will be performed in Missoula from September 2021 through August 2023. This total small business...
- This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases awards Inimmune Corporation $1.99 million to develop a Synthetic Adjuvant System. The contract is a result of the agency's SBIR Phase II solicitation seeking proposals for research and development to advance NIH and CDC missions, including alternatives to cell culture materials and cancer immunotherapy manufacturing. Placed in...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $600,000 firm-fixed-price definitive contract to Integral Molecular Inc., a small business biotechnology company, for "ADJUVANT TARGET DISCOVERY FOR VACCINES AND FOR AUTOIMMUNE AND ALLERGIC DISEASES." The contract has a completion date of June 29, 2024. Integral Molecular specializes in membrane protein research and has received numerous federal contracts and grants from agencies like the National Institutes of...
- This is a $599,234 firm fixed price contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) to Celdara Medical, a small business biotechnology company, under the Small Business Innovation Research (SBIR) program. The contract is for research to discover parasite-derived tolerogenic adjuvants, which could potentially be used in new vaccine development. Celdara Medical conducts research and...
- The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded PAI Life Sciences Inc. a $597,953 definitive contract to develop late stage adjuvant mimics based on toll-like receptor 4 agonists. As a self-certified small disadvantaged business, this contract was designated as a total small business set aside. PAI Life Sciences will provide products and services to the National Institute of Allergy and Infectious Diseases in support of their program for late stage...
- The Department of Health and Human Services' National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded a $599,980 firm fixed price contract to Tendel Therapies, Inc., a small business, for research and development services related to genetic adjuvants to promote durable anti-influenza stem antibodies in older adults. This contract was awarded under the NIH and Centers for Disease Control and Prevention's Small Business Innovation Research (SBIR) program,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $18.8 million cost-plus-fixed-fee definitive contract to Access To Advanced Health Institute (AAHI), a Seattle-based nonprofit biotech research organization, on September 21, 2018, with completion targeted for August 31, 2026. The contract supports advanced preclinical and clinical development of an intranasal recombinant amebiasis vaccine containing a liposomal adjuvant formulation incorporating toll-like receptor (TLR)...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Tolka.ai Inc. (doing business as Tolka AI Therapeutics), a for-profit small business. The contract, valued at $299,993.00, is for research and development efforts related to NIAID's mission needs and SBIR program objectives. The original solicitation included a variety of research topics,...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $599,582.00 firm fixed price contract to Virtici LLC, a for-profit limited liability company, to develop toll-like receptor agonists to strengthen sublingual vaccines. This contract is a small business set-aside. Virtici LLC is a biomedical research and development company that has received over $3 million in prior federal contracts and grants from agencies...